Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"Authorized" Generics' Short-Term Benefits Outweighed By Drag On ANDAs, GPhA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Although authorized generics may stimulate competition, they undermine the incentive to submit generic drug applications, GPhA maintains. Association will "keep our options open" in determining "next steps."

You may also be interested in...

FDA Signs Off On "Authorized" Generics; Deals Are Pro-Competitive, Agency Says

FDA is not empowered to directly regulate the timing for marketing of previously approved drug products, the agency says in response to citizen petitions from Mylan and Teva. The two companies wanted FDA to prohibit the marketing of authorized generics during a first ANDA filer's 180-day exclusivity period.

Mylan Demands FDA Response On “Authorized” Generics By July 6

A supplement to Mylan’s citizen petition requests that FDA act immediately to bar authorized generics. Mylan asserts there is no evidence suggesting that authorized generics benefit consumers.

"Authorized" Generics Reduce The Incentive For Patent Challenges, GPhA Says

"Authorized" generics reduce the incentive for generic manufacturers to challenge questionable pharmaceutical patents, the Generic Pharmaceutical Association says





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts